NASDAQ · ATPC

Agape ATP Corporation

$2.46 -$0.12 (-4.65%) 1D After hours

Key Metrics

$2.58M
Market cap
P/E · TTM
$1.51M
Revenue · TTM
−$1.92M
Net income
EPS · TTM $-9.99
Dividend yield
Free cash flow
Beta · 1Y -0.06
EBITDA · TTM −$1.92M
Gross margin 55.8%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 28
    The stock moved +113.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 28
  • Apr 27
    From its Mar 12 high, the share price fell 65%.

    Peak close $5.65 on Mar 12; trough close $2.00 on Apr 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -65%
  • Mar 10
    The stock moved +87.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 10

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.58M
Enterprise value
Shares outstanding1.0M
52-wk range$0.05 – $8.50
Avg volume · 20D3.5M
Net cash
Book value / share$114.95
IndustryServices-Health Services
ExchangeNASDAQ
About Agape ATP Corporation
IPO dateSep 17, 2018
Employees18

Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.71
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 55.8%
Operating -128.1%
Net -127.4%
FCF
ROE / ROIC -16.0% · —

Financial Health

Current ratio9.01
Quick ratio9.00
Debt / equity
Debt / EBITDA
Net cash
Working capital$21.92M

Cash Flow · TTM

Operating CF −$1.35M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

0.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings